|
**Overview**: **Antenatal Mumbai Profile****Introduction**: The Antenatal Mumbai Profile is a diagnostic tool designed to conduct pregnancy screening for the Mumbai region using serum, whole blood, and urine samples. Associated with conditions like gestational diabetes and preeclampsia, these disorders present with fatigue, swelling, and severe complications if untreated, particularly in pregnant individuals in the Mumbai region. Per the 2023 Obstetrics and Gynecology guidelines, the test employs biochemistry, hematology, clinical pathology, and serology with immunoassay, automated cell counter, and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for antenatal care in clinical settings. This diagnostic falls under pregnancy screening and targets pregnant individuals in the Mumbai region with health concerns, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its multi-sample approach ensures reliable detection.**Other Names**: Antenatal Mumbai Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, hematology, clinical pathology, and serology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by obstetric labs, this test advanced regional pregnancy diagnostics.**Purpose**: The test screens for 45 parameters including hemoglobin to guide pregnancy assessment, assess maternal health, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. Differential Count, 6. ESR, 7. Blood Group (ABO & Rh), 8. Fasting Glucose, 9. HbA1c, 10. Total Bilirubin, 11. Direct Bilirubin, 12. AST, 13. ALT, 14. ALP, 15. Total Protein, 16. Albumin, 17. Globulin, 18. Creatinine, 19. Urea, 20. Uric Acid, 21. Sodium, 22. Potassium, 23. Calcium, 24. Phosphorus, 25. TSH, 26. HIV, 27. HBsAg, 28. VDRL, 29. Urine Color, 30. Urine pH, 31. Urine Specific Gravity, 32. Urine Protein, 33. Urine Glucose, 34. Urine Ketones, 35. Urine Blood, 36. Urine Nitrite, 37. Urine Leukocytes, 38. Urine Epithelial Cells, 39. Urine RBCs, 40. Urine Casts, 41. Urine Bilirubin, 42. Urine Urobilinogen, 43. Urine Bacteria, 44. Anti-HCV, 45. Rubella IgG.**Pretest Condition**: Fasting 10-12 hours required; patients should report fatigue, swelling, or recent pregnancy changes.**Specimen**: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 48 hours (Blood), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Blood, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fatigue, swelling, prior pregnancy complications, or family history of pregnancy disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated pregnancy conditions including eclampsia, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay, automated cell counter, and microscopy and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent dietary changes can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible pregnancy complications, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early gestation stages.**Specialist Consultation**: General practitioners or specialists in obstetrics or gynecology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Glucose tolerance test, ultrasound, or genetic testing for confirmation.**Test Limitations**: The test may produce false negatives in early gestation stages or false positives in dietary variations, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Obstetrics and Gynecology Guidelines 2023, Journal of Maternal-Fetal Medicine 2024, Biochemistry 2025. |
